Login
Home
Charts
Search
Watchlist
Products

Cravatex Ltd

CRAVATEX·BSE
342.400.00%Mon, 21 Sept '26

Cravatex Ltd

CRAVATEX
BSE
342.40
0.00%
|Mon, 21 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
88Cr
Close
Close Price
342.40
Industry
Industry
Trading
PE
Price To Earnings
10.29
PS
Price To Sales
0.55
Revenue
Revenue
160Cr
Rev Gr TTM
Revenue Growth TTM
-6.52%
PAT Gr TTM
PAT Growth TTM
189.90%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
573851265532612351374032
Growth YoY
Revenue Growth YoY%
-66.3-56.5-39.5-54.5-4.2-14.419.4-10.3-6.513.4-34.739.3
Expenses
ExpensesCr
604253285334602949394036
Operating Profit
Operating ProfitCr
-2-4-2-22-21-63-2-1-3
OPM
OPM%
-3.8-10.0-3.7-9.03.6-5.80.8-26.45.4-6.6-1.5-10.2
Other Income
Other IncomeCr
663322254534
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
100000000000
PBT
PBTCr
3101402-16221
Tax
TaxCr
010010101010
PAT
PATCr
3110301-15120
Growth YoY
PAT Growth YoY%
116.2-99.1-87.014.3-14.8-68.3188.0-385.497.0440.011.1132.1
NPM
NPM%
5.42.11.01.94.80.82.4-5.910.23.74.01.4
EPS
EPS
12.03.01.91.910.31.05.6-5.320.25.26.21.7
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
573851265532612351374032
Growth YoY
Revenue Growth YoY%
-66.3-56.5-39.5-54.5-4.2-14.419.4-10.3-6.513.4-34.739.3
Expenses
ExpensesCr
604253285334602949394036
Operating Profit
Operating ProfitCr
-2-4-2-22-21-63-2-1-3
OPM
OPM%
-3.8-10.0-3.7-9.03.6-5.80.8-26.45.4-6.6-1.5-10.2
Other Income
Other IncomeCr
663322254534
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
100000000000
PBT
PBTCr
3101402-16221
Tax
TaxCr
010010101010
PAT
PATCr
3110301-15120
Growth YoY
PAT Growth YoY%
116.2-99.1-87.014.3-14.8-68.3188.0-385.497.0440.011.1132.1
NPM
NPM%
5.42.11.01.94.80.82.4-5.910.23.74.01.4
EPS
EPS
12.03.01.91.910.31.05.6-5.320.25.26.21.7

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
255266356718865532594504203174151160
Growth
Revenue Growth%
9.54.533.7101.720.5-38.511.7-15.3-59.8-14.3-13.2-6.5
Expenses
ExpensesCr
249272362694844544593534210175157164
Operating Profit
Operating ProfitCr
6-5-62421-121-30-8-2-6-4
OPM
OPM%
2.3-2.0-1.73.32.4-2.30.2-6.0-3.8-1.0-4.2-2.2
Other Income
Other IncomeCr
34445141011816101716
Interest Expense
Interest ExpenseCr
131045131413130000
Depreciation
DepreciationCr
3366151716162122
PBT
PBTCr
-7-15-1217-2-30-195866911
Tax
TaxCr
1-106211-11222
PAT
PATCr
-8-14-1211-5-31-20595579
Growth
PAT Growth%
-432.1-75.011.0186.4-144.2-549.335.0396.3-91.80.040.8189.9
NPM
NPM%
-3.1-5.2-3.51.5-0.6-5.8-3.411.72.42.84.55.4
EPS
EPS
-30.7-53.7-47.741.3-18.2-118.5-77.0228.118.718.726.333.3
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
255266356718865532594504203174151160
Growth
Revenue Growth%
9.54.533.7101.720.5-38.511.7-15.3-59.8-14.3-13.2-6.5
Expenses
ExpensesCr
249272362694844544593534210175157164
Operating Profit
Operating ProfitCr
6-5-62421-121-30-8-2-6-4
OPM
OPM%
2.3-2.0-1.73.32.4-2.30.2-6.0-3.8-1.0-4.2-2.2
Other Income
Other IncomeCr
34445141011816101716
Interest Expense
Interest ExpenseCr
131045131413130000
Depreciation
DepreciationCr
3366151716162122
PBT
PBTCr
-7-15-1217-2-30-195866911
Tax
TaxCr
1-106211-11222
PAT
PATCr
-8-14-1211-5-31-20595579
Growth
PAT Growth%
-432.1-75.011.0186.4-144.2-549.335.0396.3-91.80.040.8189.9
NPM
NPM%
-3.1-5.2-3.51.5-0.6-5.8-3.411.72.42.84.55.4
EPS
EPS
-30.7-53.7-47.741.3-18.2-118.5-77.0228.118.718.726.333.3

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
33333333333
Reserves
ReservesCr
3319717-4-31-529096104117
Current Liabilities
Current LiabilitiesCr
12011010718824421720643233124
Non Current Liabilities
Non Current LiabilitiesCr
188892921281211342332
Total Liabilities
Total LiabilitiesCr
175220208299442385365137125141146
Current Assets
Current AssetsCr
142164158247341302295126115131138
Non Current Assets
Non Current AssetsCr
33565052101837011999
Total Assets
Total AssetsCr
175220208299442385365137125141146
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
33333333333
Reserves
ReservesCr
3319717-4-31-529096104117
Current Liabilities
Current LiabilitiesCr
12011010718824421720643233124
Non Current Liabilities
Non Current LiabilitiesCr
188892921281211342332
Total Liabilities
Total LiabilitiesCr
175220208299442385365137125141146
Current Assets
Current AssetsCr
142164158247341302295126115131138
Non Current Assets
Non Current AssetsCr
33565052101837011999
Total Assets
Total AssetsCr
175220208299442385365137125141146

Cash Flow

Consolidated
Standalone
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
35-13-532-4-81441931
Investing Cash Flow
Investing Cash FlowCr
-24-43-37211442-1-13
Financing Cash Flow
Financing Cash FlowCr
38-34037-21-4-1680-1-3
Net Cash Flow
Net Cash FlowCr
50-51-232-43181721
Free Cash Flow
Free Cash FlowCr
13-13-1024-7-91821811
CFO To PAT
CFO To PAT%
-254.8101.4-44.0-679.212.538.0243.6394.861.818.7
CFO To EBITDA
CFO To EBITDA%
-646.6202.0-19.9156.231.1-551.3-473.1-248.8-176.5-19.9
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
35-13-532-4-81441931
Investing Cash Flow
Investing Cash FlowCr
-24-43-37211442-1-13
Financing Cash Flow
Financing Cash FlowCr
38-34037-21-4-1680-1-3
Net Cash Flow
Net Cash FlowCr
50-51-232-43181721
Free Cash Flow
Free Cash FlowCr
13-13-1024-7-91821811
CFO To PAT
CFO To PAT%
-254.8101.4-44.0-679.212.538.0243.6394.861.818.7
CFO To EBITDA
CFO To EBITDA%
-646.6202.0-19.9156.231.1-551.3-473.1-248.8-176.5-19.9

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5993997384759383113887988
Price To Earnings
Price To Earnings
6.91.423.418.311.610.3
Price To Sales
Price To Sales
0.20.30.30.10.10.10.20.20.60.50.50.6
Price To Book
Price To Book
1.64.310.63.7-81.8-2.6-1.90.91.10.80.70.7
EV To EBITDA
EV To EBITDA
21.3-31.3-31.87.811.5-15.7162.2-0.9-4.8-7.7-0.3-2.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
33.725.625.024.926.027.826.323.127.032.240.640.6
OPM
OPM%
2.3-2.0-1.73.32.4-2.30.2-6.0-3.8-1.0-4.2-2.2
NPM
NPM%
-3.1-5.2-3.51.5-0.6-5.8-3.411.72.42.84.55.4
ROCE
ROCE%
4.8-3.4-6.716.15.4-12.2-4.377.66.66.47.57.5
ROE
ROE%
-22.1-63.4-132.253.9460.6108.240.063.84.94.55.75.7
ROA
ROA%
-4.5-6.3-5.93.6-1.1-8.0-5.543.13.93.44.74.7
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5993997384759383113887988
Price To Earnings
Price To Earnings
6.91.423.418.311.610.3
Price To Sales
Price To Sales
0.20.30.30.10.10.10.20.20.60.50.50.6
Price To Book
Price To Book
1.64.310.63.7-81.8-2.6-1.90.91.10.80.70.7
EV To EBITDA
EV To EBITDA
21.3-31.3-31.87.811.5-15.7162.2-0.9-4.8-7.7-0.3-2.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
33.725.625.024.926.027.826.323.127.032.240.640.6
OPM
OPM%
2.3-2.0-1.73.32.4-2.30.2-6.0-3.8-1.0-4.2-2.2
NPM
NPM%
-3.1-5.2-3.51.5-0.6-5.8-3.411.72.42.84.55.4
ROCE
ROCE%
4.8-3.4-6.716.15.4-12.2-4.377.66.66.47.57.5
ROE
ROE%
-22.1-63.4-132.253.9460.6108.240.063.84.94.55.75.7
ROA
ROA%
-4.5-6.3-5.93.6-1.1-8.0-5.543.13.93.44.74.7
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Cravatex is a debt-free holding company that earns its keep from two unrelated worlds - trading textiles in India and collecting rent on a Mumbai office building - while its real growth story plays out through a UK subsidiary that designs and sells FILA and Sergio Tacchini sportswear across Europe. The company arrived at this lean structure after a defining move in late 2022, when it sold its entire domestic branded sports business to Metro Brands, exiting a loss-making operation and unlocking the value of its Mumbai properties in the process. The recurring pattern is one of licensing rather than manufacturing: the company does not own factories, holds no trading inventory, and instead ties its fortunes to brand licences, contractual leases, and a trading desk that moves other people’s goods. # Business segments Two engines of roughly equal weight - an international brand-licensing platform and a domestic trading-and-property operation - each built on assets the group already owned. ## 1. Textile trading and investment property: the Indian cash engine **A low-overhead trading desk and a leased Mumbai building together generate steady domestic income without the company ever holding inventory or running a factory.** - **No inventory, no manufacturing** - the company’s standalone operations carry zero opening or closing stock, and its energy consumption is limited to office use; it simply buys and sells textiles, mostly garments, without touching a production line. - **Regional concentration lowers complexity** - the trading activity is largely confined to south and west India, which keeps logistics simple and relationships deep in a handful of textile hubs. - **A building that pays for itself** - the company owns an investment property in Mumbai carried at a gross value of about Rs 9.6 crore but worth roughly Rs 55.8 crore at fair market value, and it leases the space to a reputed tenant under a registered agreement that locks in the rental income for a fixed period. - **Credit extended, risk spread** - customers get anywhere from 30 to 180 days to pay, but the receivables are spread across a large number of buyers with no single-customer concentration, so a default by any one of them does not threaten the business. ## 2. International branded sportswear: the European licensing platform **A wholly owned UK subsidiary designs, sources, and markets FILA and Sergio Tacchini apparel to retailers and online shoppers - it owns the customer relationship, not the brand.** - **Licences, not owned brands** - BB (UK) Limited holds the rights to distribute FILA in the UK and Middle East and Sergio Tacchini in the UK; it pays for the privilege of using names someone else built, which means it can walk away if a licence underperforms but also faces intense global competition for those same brands. - **Design-and-source model** - the subsidiary designs the products, contracts third-party factories to make them, and then sells to wholesale accounts and through e-commerce channels; it also undertakes manufacturing. - **Brexit-proofed with a German step-down** - after Britain left the EU, the group set up BB Europe GmbH in Germany as a wholly owned subsidiary of BBUK, so it could keep trading seamlessly with European clients without customs friction. - **Demand is hostage to the UK high street** - when British retail spending slows and stores close, as happened during the cost-of-living crisis, BBUK’s order book shrinks; its revenue fell from £19.3 million to £15.7 million in one year largely because of a drop in Middle East FILA sales and lower sourcing revenue from FILA’s global licensees. - **Supply shocks hit hard** - during the pandemic, shipping costs jumped three to four times normal levels, and Brexit layered on extra raw-material and logistics costs, squeezing margins on a business that already runs on thin wholesale spreads. # Group structure and partners **A deliberately simple structure - one Indian parent, one UK subsidiary, one German step-down - with no debt and all legacy domestic sports assets sold.** - The listed Indian parent, Cravatex Limited, is itself controlled by R.B. Fitness and Trading Private Limited and employs just eight people. - BB (UK) Limited, acquired in 2011, is the 100% subsidiary that holds the FILA and Sergio Tacchini licences; BB Europe GmbH, formed in 2020, sits underneath it as a wholly owned step-down to serve the EU market. - The domestic branded-sports business that once dominated the group - Cravatex Brands Limited, which held the exclusive long-term FILA licence for India and owned the Proline brand - was sold in its entirety to Metro Brands in December 2022, along with the stake held by private-equity investor Paragon Partners. - As part of that exit, the company released mortgages on its Nariman Point and Prabhadevi properties in Mumbai that had been pledged as security for CBL’s borrowings; those properties are now unencumbered.

Documents — Cravatex Ltd

  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/5qgwmtzlnonqgi7ujwc9tdnh.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/ndrylth5bkb5udlxronenhkx.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/iidwqtu0qb8ow7t4epsyc5un.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/bsry0xe93i6aaoekviadfiyl.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/64wst8qsmbztw6zg00jsfymm.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/wtevtrjoi8xd5lhhdqq2afyt.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/5bax5gofyun8zjjroeuwynpr.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/v7jip32qoa2mulfc5j4kocow.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/cx2tz7k43p70sex4nyil2dwk.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/uwfsvbh7wkyybb4q2uprkk7j.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/noqdp332tpyvzdar37tkt2vy.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/6doywvrxcbnbcmio8ivhebaa.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/pm8ihrka48ol2nhwmy480s5m.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/jolfenagbsg54wry6srqjxj4.pdf